Monopar Therapeutics(MNPR)

Search documents
Monopar Therapeutics(MNPR) - 2024 Q1 - Quarterly Report
2024-05-09 11:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (I.R.S. employer identification number) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. FORM 10-Q (Exact name of registrant as specified in its chart ...
Monopar Therapeutics(MNPR) - 2024 Q1 - Quarterly Results
2024-05-09 11:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K | Delaware | 001-39070 | 32-0463781 | | --- | --- | --- | | (State or other jurisdiction | (Commission | (I.R.S. Employer | | of incorporation) | File Number) | Identification No.) | 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091 (Address of principal executive offices) (Zip Code) (847) 388-0349 Registrant's telephone number, including area code CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of ...
Monopar Therapeutics(MNPR) - 2023 Q4 - Annual Report
2024-03-28 11:01
☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K For the Fiscal Year Ended December 31, 2023 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 32-0463781 (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification number) 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091 (Address of principal execut ...
Monopar Therapeutics(MNPR) - 2023 Q4 - Annual Results
2024-03-28 11:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Address of principal executive offices) (Zip Code) (847) 388-0349 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) | Delaware | 001-39070 | 32-0463781 | | --- | --- | --- | | (State or other jurisdiction | (Commission | (I.R.S. Employer | | of inc ...
Monopar Therapeutics(MNPR) - 2023 Q3 - Quarterly Report
2023-11-09 12:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 32-0463781 ( ...
Monopar Therapeutics(MNPR) - 2023 Q2 - Quarterly Report
2023-08-10 11:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 32-0463781 (State ...
Monopar Therapeutics(MNPR) - 2023 Q1 - Quarterly Report
2023-05-11 11:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 32-0463781 (State or other jurisdi ...
Monopar Therapeutics(MNPR) - 2022 Q4 - Annual Report
2023-03-23 11:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (State or other jurisdiction of incorporation or organization) Delaware 32-0463781 (I.R.S. employer identification number) (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from_______________ to ________________ Commissi ...
Monopar Therapeutics(MNPR) - 2022 Q3 - Quarterly Report
2022-11-10 13:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 32-0463781 (State or other jurisdiction of incorporation or organization) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (I.R.S. employer identification number) For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTI ...
Monopar Therapeutics(MNPR) - 2022 Q2 - Quarterly Report
2022-08-11 12:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 32-0463781 (State or other jurisdic ...